Global Medical Marijuana 2017 Industry Trends, Sales, Supply, Demand, Analysis & Forecast to 2022

WiseGuyReports.com adds “Medical Marijuana Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022”

PUNE, INDIA, November 22, 2017 /EINPresswire.com/ — Summary

WiseGuyReports.com adds “Medical Marijuana Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022” reports to its database.

This report provides in depth study of “Medical Marijuana market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Medical Marijuana Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

This report studies Medical Marijuana in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering 
Cara Therapeutics 
Cannabis Sativa 
CannaGrow Holdings 
United Cannabis 
Growblox Sciences 
GreenGro Technologies 
GW Pharmaceuticals 
Lexaria Corp 
MMJ America

Request a Sample Report @   https://www.wiseguyreports.com/sample-request/2512149-global-medical-marijuana-market-professional-survey-report-2017

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into 
Cannabis Plant Dry Goods 
Cannabis Resin 
Cannabis Oil

By Application, the market can be split into 
Chronic Pain 
Arthritis 
Migraine 
Cancer 
Other

By Regions, this report covers (we can add the regions/countries as you want) 
North America 
China 
Europe 
Southeast Asia 
Japan 
India

At any Query @ https://www.wiseguyreports.com/enquiry/2512149-global-medical-marijuana-market-professional-survey-report-2017

Table of Contents 

Global Medical Marijuana Market Professional Survey Report 2017 
1 Industry Overview of Medical Marijuana 
1.1 Definition and Specifications of Medical Marijuana 
1.1.1 Definition of Medical Marijuana 
1.1.2 Specifications of Medical Marijuana 
1.2 Classification of Medical Marijuana 
1.2.1 Cannabis Plant Dry Goods 
1.2.2 Cannabis Resin 
1.2.3 Cannabis Oil 
1.3 Applications of Medical Marijuana 
1.3.1 Chronic Pain 
1.3.2 Arthritis 
1.3.3 Migraine 
1.3.4 Cancer 
1.3.5 Other 
1.4 Market Segment by Regions 
1.4.1 North America 
1.4.2 China 
1.4.3 Europe 
1.4.4 Southeast Asia 
1.4.5 Japan 
1.4.6 India

2 Manufacturing Cost Structure Analysis of Medical Marijuana 
2.1 Raw Material and Suppliers 
2.2 Manufacturing Cost Structure Analysis of Medical Marijuana 
2.3 Manufacturing Process Analysis of Medical Marijuana 
2.4 Industry Chain Structure of Medical Marijuana

…..

8 Major Manufacturers Analysis of Medical Marijuana 
8.1 Cara Therapeutics 
8.1.1 Company Profile 
8.1.2 Product Picture and Specifications 
8.1.2.1 Product A 
8.1.2.2 Product B 
8.1.3 Cara Therapeutics 2016 Medical Marijuana Sales, Ex-factory Price, Revenue, Gross Margin Analysis 
8.1.4 Cara Therapeutics 2016 Medical Marijuana Business Region Distribution Analysis 
8.2 Cannabis Sativa 
8.2.1 Company Profile 
8.2.2 Product Picture and Specifications 
8.2.2.1 Product A 
8.2.2.2 Product B 
8.2.3 Cannabis Sativa 2016 Medical Marijuana Sales, Ex-factory Price, Revenue, Gross Margin Analysis 
8.2.4 Cannabis Sativa 2016 Medical Marijuana Business Region Distribution Analysis 
8.3 CannaGrow Holdings 
8.3.1 Company Profile 
8.3.2 Product Picture and Specifications 
8.3.2.1 Product A 
8.3.2.2 Product B 
8.3.3 CannaGrow Holdings 2016 Medical Marijuana Sales, Ex-factory Price, Revenue, Gross Margin Analysis 
8.3.4 CannaGrow Holdings 2016 Medical Marijuana Business Region Distribution Analysis 
8.4 United Cannabis 
8.4.1 Company Profile 
8.4.2 Product Picture and Specifications 
8.4.2.1 Product A 
8.4.2.2 Product B 
8.4.3 United Cannabis 2016 Medical Marijuana Sales, Ex-factory Price, Revenue, Gross Margin Analysis 
8.4.4 United Cannabis 2016 Medical Marijuana Business Region Distribution Analysis 
8.5 Growblox Sciences 
8.5.1 Company Profile 
8.5.2 Product Picture and Specifications 
8.5.2.1 Product A 
8.5.2.2 Product B 
8.5.3 Growblox Sciences 2016 Medical Marijuana Sales, Ex-factory Price, Revenue, Gross Margin Analysis 
8.5.4 Growblox Sciences 2016 Medical Marijuana Business Region Distribution Analysis 
8.6 GreenGro Technologies 
8.6.1 Company Profile 
8.6.2 Product Picture and Specifications 
8.6.2.1 Product A 
8.6.2.2 Product B 
8.6.3 GreenGro Technologies 2016 Medical Marijuana Sales, Ex-factory Price, Revenue, Gross Margin Analysis 
8.6.4 GreenGro Technologies 2016 Medical Marijuana Business Region Distribution Analysis 
8.7 GW Pharmaceuticals 
8.7.1 Company Profile 
8.7.2 Product Picture and Specifications 
8.7.2.1 Product A 
8.7.2.2 Product B 
8.7.3 GW Pharmaceuticals 2016 Medical Marijuana Sales, Ex-factory Price, Revenue, Gross Margin Analysis 
8.7.4 GW Pharmaceuticals 2016 Medical Marijuana Business Region Distribution Analysis 
8.8 Lexaria Corp 
8.8.1 Company Profile 
8.8.2 Product Picture and Specifications 
8.8.2.1 Product A 
8.8.2.2 Product B 
8.8.3 Lexaria Corp 2016 Medical Marijuana Sales, Ex-factory Price, Revenue, Gross Margin Analysis 
8.8.4 Lexaria Corp 2016 Medical Marijuana Business Region Distribution Analysis 
8.9 MMJ America 
8.9.1 Company Profile 
8.9.2 Product Picture and Specifications 
8.9.2.1 Product A 
8.9.2.2 Product B 
8.9.3 MMJ America 2016 Medical Marijuana Sales, Ex-factory Price, Revenue, Gross Margin Analysis 
8.9.4 MMJ America 2016 Medical Marijuana Business Region Distribution Analysis

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2512149

Continued….

Contact Us: sales@wiseguyreports.com

Ph: +1-646-845-9349 (US) ; Ph: +44 208 133 9349 (UK)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Hair Loss&growth Treatments and Products Market – Asia Industry Analysis, Size, Share, Growth, Trends and Forecast– 2021

Wise.Guy12

Wise.Guy.

The report provides in depth study of “Hair Loss&growth Treatments and Products” using SWOT analysis i.e. Strength, Weakness, Opportunities to organization

PUNE, INDIA, November 22, 2017 /EINPresswire.com/ — Hair Loss&growth Treatments and Products Market Analysis And Forecast

With the slowdown in world economic growth, the Hair Loss&growth Treatments and Products industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Hair Loss&growth Treatments and Products market size to maintain the average annual growth rate of 2.06% from 1460 million $ in 2013 to 1552 million $ in 2016, BisReport analysts believe that in the next few years, Hair Loss&growth Treatments and Products market size will be further expanded, we expect that by 2021, The market size of the Hair Loss&growth Treatments and Products will reach 1783 million $. 

This Report covers the Major Players’ data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. 

Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size. Also cover different industries clients’ information, which is very important for the Major Players. If you need more information, please contact BisReport

Section 1: Free——Definition

Section 2: 800 USD——Major Player Market Share and Market Segmentation by Region 
China 
India 
Indonesia 
Pakistan 
Bangladesh 
Japan 
Philippines 
Vietnam 
Turkey 
Thailand 
South Korea 
Malaysia 
Saudi Arabia 
Taiwan China 
The United Arab Emirates 
Singapore

Section 3: 900 USD——Major Player Detail 
Shiseido 
Rohto 
Unilever 
Taisho 
Angfa 
L’Oreal 
Kaminomoto 
Merck 
Yanagiya Honten 
Amorepacific 
Procter & Gamble 
Himalaya 
Gerolymatos International 
Merz Pharma 
Leader Teck 
Vasu Healthcare 
VLCC 
Ales Group 
Shanxi Ante 
Wansheng Pharmaceutical 
Advanced Skin and Hair 
Humanwell Healthcare 
Topfond 
Lifes2good 
Bawang 
YNK Pharmaceutical 
Apollo 
Jingxiutang 
Rogaine 
Marico 
Zhang Guang 101 
Softto

Section (4 5): 900 USD—— 
Industry Segmentation (Pharmacies, Hospitals, Supermarkets, Individual) 
Channel (Direct Sales, Distributor) Segmentation

Section 6: 800 USD——Trend (2017-2021)

Section 7: 700 USD——Downstream Consumer

Section 8: 200 USD——Cost Structure

Section 9: 500 USD——Conclusion

 

Request For Sample Report @ https://www.wiseguyreports.com/sample-request/2526381-asia-hair-loss-growth-treatments-and-products-market-report-2017                                        

                                                        

Table of Contents:

Section 1 Hair Loss&growth Treatments and Products Definition

Section 2 Asia Hair Loss&growth Treatments and Products Market Major Player Share and Market Overview 
    2.1 Asia Major Player Hair Loss&growth Treatments and Products Business Revenue 
    2.2 Asia Hair Loss&growth Treatments and Products Market Segmentation (Region Level) Market Size (Value) 2013-2016 
    2.3 Asia Hair Loss&growth Treatments and Products Market Overview

Section 3 Major Player Hair Loss&growth Treatments and Products Business Introduction 
    3.1 Shiseido Hair Loss&growth Treatments and Products Business Introduction 
      3.1.1 Shiseido Hair Loss&growth Treatments and Products Revenue, Growth Rate and Gross profit 2013-2016 
      3.1.2 Shiseido Hair Loss&growth Treatments and Products Business Distribution by Region 
      3.1.3 Shiseido Interview Record 
      3.1.4 Shiseido Hair Loss&growth Treatments and Products Business Profile 
      3.1.5 Shiseido Hair Loss&growth Treatments and Products Specification

    3.2 Rohto Hair Loss&growth Treatments and Products Business Introduction 
      3.2.1 Rohto Hair Loss&growth Treatments and Products Revenue, Growth Rate and Gross profit 2013-2016
      3.2.2 Rohto Hair Loss&growth Treatments and Products Business Distribution by Region 
      3.2.3 Interview Record 
      3.2.4 Rohto Hair Loss&growth Treatments and Products Business Overview 
      3.2.5 Rohto Hair Loss&growth Treatments and Products Specification

    3.3 Unilever Hair Loss&growth Treatments and Products Business Introduction 
      3.3.1 Unilever Hair Loss&growth Treatments and Products Revenue, Growth Rate and Gross profit 2013-2016 
      3.3.2 Unilever Hair Loss&growth Treatments and Products Business Distribution by Region 
      3.3.3 Interview Record 
      3.3.4 Unilever Hair Loss&growth Treatments and Products Business Overview 
      3.3.5 Unilever Hair Loss&growth Treatments and Products Specification

    3.4 Taisho Hair Loss&growth Treatments and Products Business Introduction 
    3.5 Angfa Hair Loss&growth Treatments and Products Business Introduction 
    3.6 L’Oreal Hair Loss&growth Treatments and Products Business Introduction 

Section 4 Asia Hair Loss&growth Treatments and Products Market Segmentation (Industry Level) 
    4.1 Asia Hair Loss&growth Treatments and Products Market Segmentation (Industry Level) Market Size 2013-2016 
    4.2 Different Industry Trend 2013-2016 
    4.3 Asia Hair Loss&growth Treatments and Products Market Segmentation (Industry Level) Analysis

 Continued…….

 

Enquiry Before Buy @ https://www.wiseguyreports.com/enquiry/2526381-asia-hair-loss-growth-treatments-and-products-market-report-2017                                                                     

                                                                                                                                                             

CONTACT US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

 

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Healthcare Market 2017 Asia Pacific Analysis & Forecast to 2022 Market Research Report

Wise.Guy12

Wise.Guy.

The report provides in depth study of “Healthcare” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization

PUNE, INDIA, November 22, 2017 /EINPresswire.com/ — Healthcare Market Analysis And Forecast

This Report covers the Major Players’ data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. 

Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size. Also cover different industries clients’ information, which is very important for the Major Players. If you need more information, please contact BisReport

Section 1: Free——Definition

Section 2: 800 USD——Major Player Market Share and Market Segmentation by Region 
China 
Japan 
India 
Southeast Asia 
Australia

Section 3: 900 USD——Major Player Detail 
Pfizer 
Hoffmann-La Roche 
GlaxoSmithKline 
Merk & Co 
Sanofi 
Novartis 
Medtronic 
Johnson & Johnson 
Daiichi Sankyo 
Sun Pharmaceutical Industries 
Abbott

Section (4 5 6): 500 USD—— 
Type Segmentation (Healthcare Services, Pharmaceuticals, Medical Equipment) 
Industry Segmentation (Hospitals and Outpatient Care Centers, Home Health Care and Residential Nursing Care Services, Medical and Diagnostic Laboratory Services, Dental Services, Others) 
Channel (Direct Sales, Distributor) Segmentation

Section 7: 400 USD——Trend (2017-2021)

Section 8: 300 USD—— Type Detail

Section 9: 700 USD——Downstream Consumer

Section 10: 200 USD——Cost Structure

Section 11: 500 USD——Conclusion

 

Request For Sample Report @ https://www.wiseguyreports.com/sample-request/2526382-asia-pacific-healthcare-market-report-2017                                       

                                                        

Table of Contents:

Section 1 Healthcare Definition

Section 2 Asia Pacific Healthcare Market Major Player Share and Market Overview 
    2.1 Asia Pacific Major Player Healthcare Business Revenue 
    2.2 Asia Pacific Healthcare Market Segmentation (Region Level) Market Size (Value) 2013-2016 
    2.3 Asia Pacific Healthcare Market Overview

Section 3 Major Player Healthcare Business Introduction 
    3.1 Pfizer Healthcare Business Introduction 
      3.1.1 Pfizer Healthcare Revenue, Growth Rate and Gross profit 2013-2016 
      3.1.2 Pfizer Healthcare Business Distribution by Region 
      3.1.3 Pfizer Interview Record 
      3.1.4 Pfizer Healthcare Business Profile 
      3.1.5 Pfizer Healthcare Specification

    3.2 Hoffmann-La Roche Healthcare Business Introduction 
      3.2.1 Hoffmann-La Roche Healthcare Revenue, Growth Rate and Gross profit 2013-2016 
      3.2.2 Hoffmann-La Roche Healthcare Business Distribution by Region 
      3.2.3 Interview Record 
      3.2.4 Hoffmann-La Roche Healthcare Business Overview 
      3.2.5 Hoffmann-La Roche Healthcare Specification

    3.3 GlaxoSmithKline Healthcare Business Introduction 
      3.3.1 GlaxoSmithKline Healthcare Revenue, Growth Rate and Gross profit 2013-2016 
      3.3.2 GlaxoSmithKline Healthcare Business Distribution by Region 
      3.3.3 Interview Record 
      3.3.4 GlaxoSmithKline Healthcare Business Overview 
      3.3.5 GlaxoSmithKline Healthcare Specification

    3.4 Merk & Co Healthcare Business Introduction 
    3.5 Sanofi Healthcare Business Introduction 
    3.6 Novartis Healthcare Business Introduction 

Section 4 Asia Pacific Healthcare Market Segmentation ( Type Level) 
    4.1 Asia Pacific Healthcare Market Segmentation ( Type Level) Market Size 2013-2016 
    4.2 Different Healthcare Market Segmentation ( Type Level) Market Size Growth Rate 2013-2016 
    4.3 Asia Pacific Healthcare Market Segmentation ( Type Level) Analysis

 Continued…….

 

Enquiry Before Buy @ https://www.wiseguyreports.com/enquiry/2526382-asia-pacific-healthcare-market-report-2017                                                                    

                                                                                                                                                             

CONTACT US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

CVR Medical Meets Critical Milestone. Deploys Wireless System at Thomas Jefferson University

CVR Medical Corp. (OTCQB:CRRVF)

VANCOUVER, BRITISH COLUMBIA, CANADA, November 21, 2017 /EINPresswire.com/ — CVR Medical Corp. (TSX.V: CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical”) announces the full integration of the “Carotid Stenotic Scan (CSS)” wireless device into its late stage, ongoing clinical trials being conducted at Thomas Jefferson University. The wireless system is the key component of the novel device’s efficient and user-friendly design. The wireless Intellectual Property in CVR’s portfolio fortifies barrier to entry.

“We have now finalized the key milestone, by deploying the wireless version of the CSS at Thomas Jefferson University. The wireless version of the CSS has been 3 years in design, development, validation and now deployment” says CVR COO Tony Robinson. “This is one of the many state-of-the-art advantages we’ve built into the device, and we believe it goes a long way in reducing cost, easing operation and streamlining entry into the marketplace.” The clinician can easily incorporate this revolutionary technology into their office without the need of a certified technician.

To expedite FDA approval, CVR will add additional clinical sites for pivotal trials with the wireless device in anticipation of market launch in 2018.

For additional information on the organization, leadership, and current news please visit the company website www.CVRMed.com.

About CVR Medical

CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the "Joint Venture"). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.

ON BEHALF OF THE BOARD:

(signed) "Peter Bakema"
CEO, President & Director

For further information contact:

Peter Bakema, CEO, President and Director
Telephone: (734) 718-5115
Email: info@cvrmed.com
or
Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888

This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.

THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Peter Bakema
CVR Medical Corp.
734-718-5115
email us here


Source: EIN Presswire

Author Announces The Availability Of The Website For Her Self-Help Book

The Tail Wags the Dog: A Psychologist Reveals Two Hundred Life Lessons Learned from Her Patients

Author Announces The Availability Of The Website For Her Self-Help Book

GETZVILLE, NY, UNITED STATES, November 21, 2017 /EINPresswire.com/ — Following the successful launch of the book entitled The Tail Wags the Dog: A Psychologist Reveals Two Hundred Life Lessons Learned from Her Patients, Dr. Amy Beth Taublieb, the author of this unique book, announces the availability of her website which she composed together with her publishing company. This newly designed website offers quick and easy access to vital information and features. It offers an overview of her newest book that will make the reader beg for more.

It is highly known that The Tail Wags the Dog: A Psychologist Reveals Two Hundred Life Lessons Learned from Her Patients is a combination of the expertise of a doctoral level clinician with the practical and easy-to-understand presentation relevant to the lay reader. It is a collection of two hundred life lessons Dr. Taublieb learned from working with virtually thousands of patients as together, in the therapy room, they navigated various life struggles. The result – a book addressing a wide variety of issues peppered with Dr. Taublieb's wisdom gleaned from performing therapy and assessment in both outpatient and inpatient settings for almost three decades.

With the goal of continuing to share her clinical expertise to all who are facing emotional/psychological challenges, Dr. Taublieb's website includes the following features: Homepage – where the readers can see an overview of what her self-help book is all about; The Book Page – directs readers to a more detailed information about the book; The Author Page – contains details about Dr. Taublieb and her clinical background; The Order Page – where the readers can see how to purchase the book; and lastly The Contact Page – where the readers can get support and information regarding the product.

The website will be updated on a regular basis in order to keep the public updated on the latest news about this book. Dr. Taublieb invites everyone to explore the website and encourage friends and family members to do the same.

About the Author:
Dr. Amy Beth Taublieb is a licensed psychologist who has been doing therapy and assessment in outpatient and inpatient settings for almost three decades. Be it with adults, couples, children, or families, her therapeutic abilities are respected by the lay public as well as by her peers. In addition to her therapeutic expertise, she is frequently called upon as a consultant to businesses for interpersonal mediation, and, to intervene with organizational employees when a psychologically traumatic critical incident occurs. Dr. Taublieb is also known for her entertaining, yet informative workshops and in-services for professionals as well as the lay public. In addition, Dr. Taublieb is no stranger to the legal system, as she is utilized by the courts to provide psychological assessments, custodial evaluations, expert testimony, coparenting therapy, and evaluations to determine the validity of sexual abuse allegations. Frequently appearing in the media, Dr. Taublieb is a regular guest on television shows and has been quoted in various national publications on issues of psychological relevance. When not working, Dr. Taublieb enjoys spending time with her cotherapist (a Maltese dog named Matza) who joins her in her therapy sessions, and who has managed to make an appearance throughout this book when he deemed it to be appropriate.

Product details:
Paperback: 120 pages
Publisher: BookBlastPro Inc. (July 22, 2017)
Language: English
ISBN-10: 1947352911
ISBN-13: 978-1947352919
Product Dimensions: 8.5 x 0.3 x 8.5 inches

Book Availability:
Amazon – http://goo.gl/hfZ7a4
Barnes & Noble – http://goo.gl/CYbmWZ
PrWeb – http://goo.gl/ahMibX

Dr. Amy Beth Taublieb
.
8885040951
email us here


Source: EIN Presswire

PetVivo Receives Uppie Award for “Best Medical Technologies for Human or Animals

Petvivo Holdings Inc. (OTCMKTS:PETV)

MINNEAPOLIS, MINNESOTA, USA, November 21, 2017 /EINPresswire.com/ — Press Release PetVivo Receives Uppie Award for “Best Medical Technologies for Human or Animals”
(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com)
Created:
Tuesday, 11-21-2017
PRESS RELEASE
PETVIVO RECIEVES UPPIE AWARD FOR “BEST MEDICAL TECHNOLOGIES FOR HUMAN OR ANIMALS”.
PetVivo Holdings, Inc. OTCPINK: PETV (www.petvivo.com) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets and people is pleased to announce receiving the Uppie Award for “Best Medical Technologies for Human or Animals”, category. Prior to the award announcements, Petvivo was nominated for three categories; Best CEO, Best Medical Technologies for Humans or Animals and Best Scientific Medical Products.
“Petvivo continues to move forward. Our product is attracting the attention from both the investment and medical communities. The public is growing more aware of the company as we near our date for commercial production. We want to thank Uptick Newswire and the Uppie Awards for their recognition of our progress”, said Mr. Wes Hayne, CEO of Petvivo Holdings, Inc.
The Uppie Awards are produced by Uptick Newswire, an Investor Relations firm that provides services to publicly-traded micro-cap and nano-tech companies on the OTC, NYSE and CSE exchanges. The awards ceremony took place November 3rd, 2017 at the Flamingo Hotel in Las Vegas, Nevada, and was attended by micro-cap investors, boutique hedge-fund managers as well as local and national media outlets.
Mr. John Lai, the President of Petvivo Holdings, accepted the award, stating, “I want to thank the Academy…. opps, wrong city and speech (laughing). Seriously, I want to thank the Uppie Awards on behalf of the Company. It is an honor to accept this award. We look forward to next year.”
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:
Wes Hayne
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
Main: (612) 296-7305
Direct: (763) 443-7272

Wes Hayne
Petvivo Holdings, Inc.
612-296-7305
email us here


Source: EIN Presswire

5 British Cannabis Companies to Keep an Eye On

CIITECH UK CBD

The UK therapeutic cannabis industry has grown to be the largest in Europe and could challenge the global medical cannabis industry.

LONDON, LONDON, UNITED KINGDOM, November 21, 2017 /EINPresswire.com/ — For a long time understood to be too conservative a culture to allow for government reform for medical cannabis, the country has quietly been cultivating it’s own therapeutic cannabis industry that has grown to be the largest in Europe and looks set to take on the global industry.

The following 5 British Cannabis Companies are highlighted for insight, keep an eye on this emerging cannabis country, keep an eye on British made CBD.

1. GW Pharmaceuticals
No list of UK cannabis companies would be complete without a mention of GW Pharma. The worlds largest cannabis company, and the one with current FDA approved cannabis medications in the market. British founded by Justin Glover in 1999, when most countries we’re oblivious to the concept of cannabis as a treatment.

GW biopharmaceutical company known for its multiple sclerosis treatment product Nabiximols. Under the brand ‘Sativex’ it is the first cannabis plant derivative medication to gain market approval in any country.

With a market cap of $3bn, and expected approval on it’s CBD product Epidiolex this is a British cannabis company to keep an eye on.

2. CBDBros
One of the first movers in the UK CBD industry and continue to grow despite their many detractors. The company have no problems stating on their website they extract CBD from indica strains (ie: not hemp and therefore not legal).
The company is well known for well-priced, basic but effective products.

This is a company that will either continue to grow and ride the regulation wave or could find themselves in hot water with the authorities. Either way, keep an eye on CBDbro.s

3. LoveHemp
LoveHemp was the first lifestyle CBD brand to enter the UK market in 2015. With a distinctive rustic packaging and branding, this is a brand that is positioning itself in the premium market with value prices. LoveHemp products are well received amongst the industries early adopters.

This is a company that is going the distance, attention to detail on both product quality and brand will enable this company to continue it’s youthful market growth.

4. CanaVape
Another of the countries early movers. CanaVape hit the market in 2015 with what fast became recognized as the market leading CBD eLiquid range. Unlike other companies delving into flavorings to enhance the vape experience, CanaVape turned to terpenes to add flavor and therapeutic effect.

CanaVape have a wide range of CBD & CBG eLiquids and has recently created a line of CBD capsules and oils. With Mixed Martial Art (UFC) sponsorships, this is a strong sports brand for vaping enthusiasts… keep an eye on their new product lines.

5. CIITECH
A relative new entrant in the UK therpeautic cannabis market, though the founder has long roots in the Israeli medical cannabis industry. CIITECH has a focus on research and innovative product development. The company recently announced a pre-clinical trial with Professor Raphael Mechoulam to investigate the potential of CBD to treat Asthma. The company say’s they have more studies underway.

CIITECH sells two CBD brands, Provacan is the classic CBD range including; oil, eliquid and balm. Herbalica is a range of traditional herbal remedies with ‘a boost of cbd’ the line includes; CalmTime, HisTime, HerTime, MindTime, NightTime. Keep an eye on CIITECH as they use old skool science to prove and validate their way to market share.

This is a fast-growing industry with figures revealing 250,000 people now use CBD potion on a regular basis.

Cannabis Trades Association UK also states there are now around 1,000 new users each month, despite the oil being shrouded in controversy.

Michael Avery
02034567823
email us here
UK CBD News


Source: EIN Presswire

Poor Quality Probiotics May Be Dangerous for Your Health, Says CEO of Amazing 4U2 Probiotic

Amazing 4U2

Amazing4U2

probiotics

probiotics

We had to change our lifestyle entirely for a life where we do not live to eat; we eat to live.”

— Luis Abarca

CORNWALL, N.Y., UNITED STATES, November 21, 2017 /EINPresswire.com/ — Luis Abarca, CEO and Founder of Amazing 4U2 Probiotic does not claim to be a doctor or a dietician, but he has some serious advice for anyone thinking about taking probiotics as a supplement.

When Abarca’s wife was first diagnosed with Rheumatoid Arthritis, an autoimmune disease, the family investigated a variety of alternative healing methods, including a healthy probiotic, in order to help her with the detoxification process.

“We had to change our lifestyle entirely for a life where we do not live to eat; we eat to live,” explains Abarca.

But the Abarca’s search for an effective probiotic ended in failure.

The couple was looking for a high-quality probiotic with certain specifications. They wanted to find a probiotic that was 100% natural and GMO free, soy free, corn free, dairy free, gluten free, wheat free, egg free, nut free, fish and shellfish free; also vegan friendly, without artificial ingredients, sweeteners or preservatives.

But their search ended in frustration. In the course of his investigations, however, Abarca made some startling discoveries. He found that many probiotics contain fillers and additives that may actually cause harm to the user.

“In some cases, the active ingredients are marked as ‘proprietary blends.’ What this really means is that the manufacturer can hide ingredients that may be unknown to the public,” Abarca explains. “I was shocked to discover that even the well-known brands that have great marketing, or great sponsors like doctors and health practitioners, are guilty of this questionable tactic.”

Many brand name probiotics are not simply guilty of just being low quality, they also contain ingredients that should not be consumed. The labels fail to mention any specific strains of probiotics which means that the consumer is unaware of what they are digesting or indeed if it will work at all for their ailment.

Abarca points to a certain famous brand which is one of the most frequently prescribed probiotics, as an example. It contains only 1 billion CFU (Colony Forming Units) and one strain. Its ingredients consist of, among others, sodium caseinate, sucrose, titanium dioxide, propyl gallate, etc. Some of these may be safe to consume but they act as fillers, emulsifiers, or binders that are not needed or should be avoided.

Sodium caseinate, for example, is not entirely harmful, but most people would not be aware that it is made from casein, a milk protein, so it would not be wise for a lactose intolerant person to consume a probiotic with this ingredient.

On the other hand, titanium dioxide is a carcinogenic product that should not be consumed by anyone. It is widely used as a whitening agent for food, cosmetics and paints, but is not recommended for human consumption.

And propyl gallate is known to cause allergic reactions in the form of an asthma attack. It can also cause stomach and skin irritation, liver damage, kidney damage and may also increase the chance of developing cancer.

Other famous probiotics contain maltodextrin, which the FDA considers to be a safe food additive. It’s a starch used as a thickener, filler, or preservative in many processed foods. Most people can consume it in moderate amounts, but because it has a high glycemic index, maltodextrin can cause spikes in blood sugar. Sugar sensitive individuals are advised not to take this additive. Furthermore, some side effects may include allergic reactions, unexplained weight gain, bloating and flatulence which are contradictory to the use of probiotics.

Other manufacturers use stearic acid, guar gum, or sodium carbonate. These are not necessarily harmful and are also FDA approved but they are slightly toxic or have some dangerous side effects, such as skin irritation, organ toxicity and neurotoxicity, vomiting or diarrhea. Stearic acid can also adversely affect the respiratory system, nervous system and brain, which has been noted in studies conducted on animals.

As a result of his findings, Abarca created his own all-natural brand of probiotic under the brand name of Amazing 4U2 Probiotic. It has 13 unique strains consisting of 50 billion live CFU (Colony Forming Units), which can support a healthy digestive tract, reduce “leaky gut” syndrome, replenish the immune system, help infections such as vaginal, sinus, or GI, provide post-antibiotic friendly bacteria recovery and help sensitive stomachs for diarrhea, constipation, bloating, IBS (Irritable Bowel Syndrome), SIBO, etc.

Probiotics are one of the most commonly used natural products in the U.S., being used by over 4 million adults. Consumers are encouraged to become informed about what they are ingesting, and choose their brand with care.

Amazing 4U2 Probiotics are produced under the highest possible standards and are being offered on Amazon for the lowest possible price.

For more information visit Amazon or the company’s website at www.amazing4u2.com

Luis Abarca
Amazing 4u2
1-844-242-9237
email us here


Source: EIN Presswire

Technical Associates of Charlotte Joins Reliability Partners

The Reliability Partners network gains from collaboration with the leading vibration analysis training and certification organization

The team of instructors at Technical Associates of Charlotte is one of the most knowledgeable and experienced anywhere in the world.”

— David Berry

FORT MYERS, FLORIDA, UNITED STATES, November 21, 2017 /EINPresswire.com/ — Reliabilityweb.com®, creator of Uptime® Elements™ – A Reliability Framework and Asset Management System™, is proud to announce Technical Associates of Charlotte, a world-class training and certification organization, as a Reliability Partner.

James E. Berry, P.E., President, Technical Associates of Charlotte, expressed a warm welcome and stated, "I would like to personally invite members of the Reliabilityweb.com community to explore the numerous vibration services, seminars and products that Technical Associates of Charlotte have developed over the past 30+ years. This fascinating vibration technology is my continuing passion that I love to share with others! I am glad to have a new group of reliability leaders join us in this captivating journey!"

“We are honored that Technical Associates of Charlotte has joined the Reliability Partner network, an eco-system of solution providers that empower the implementation of Uptime Elements – A Reliability Framework and Asset Management System,” states Terrence O’Hanlon, CEO, Reliabilityweb.com. “There is no organization that has trained or certified more vibration analysis professionals than Technical Associates of Charlotte and we look forward to making their courses and professional certification available to a new community.”

“The team of instructors at Technical Associates of Charlotte is one of the most knowledgeable and experienced anywhere in the world,” stated David Berry, Vice President, Technical Associates of Charlotte. “That experience allows their teaching to go beyond the theory into application, which will benefit the student once they return to the field. Our instructors know that the real-world and the classroom are two different things, and we diligently prepare our students for success.”

Reliability Partners enhance the business effectiveness and sustainability of reliability and asset management through:

• Peer-to-peer collaboration; 
• A deep delivery network of solution providers;
• Professional development in all areas of condition monitoring and reliability;
• Expanding reliability awareness in non-traditional areas;
• Focused project management methodology;
• Benchmarking and sharing of best practices;
• Research activities.

About Technical Associates of Charlotte, founded in 1961:

Technical Associates of Charlotte is a full-service consulting engineering company that strives to provide the most informative and up-to-date diagnostic and training services, developed by knowledgeable engineers and instructors having great expertise and continuing real-world experience. Technical Associates of Charlotte has trained over 23,000 students in live instructor-led classes and certified approximately 15,000 vibration professionals worldwide. They developed the world renowned “Illustrated Vibration Diagnostic Wall Chart” that has been acquired by analysts in over 75 countries throughout the world.

Technical Associates of Charlotte maintains one the highest levels of customer service in the industry. Technical Associates of Charlotte team members work with the values of honesty, integrity, respect, kindness and a sense of social responsibility.

2018 Training Schedules and on-site course details are available here:
www.technicalassociates.net

About Reliabilityweb.com:

Created in 1999, Reliabilityweb.com is a community of knowledge and a community of practice focused on advancing reliability and asset management to make stakeholders safer and more successful. The Reliabilityweb.com team works with integrity, authenticity, responsibility and aligns our work to delivery of our aim.

More details are available at www.reliabilityweb.com

Terrence O'Hanlon, CMRP, CEO
Reliabilityweb.com
239-333-2500 ext. 111 
email us here


Source: EIN Presswire

Global Dental CAD/CAM Market 2017 Share, Trend, Segmentation, Opportunities and Forecast to 2027

WiseGuyReports.com adds “Dental CAD/CAM Market 2017 Global Analysis, Growth, Trends, Opportunities Research Report Forecasting to 2027”reports to its database.

PUNE, INDIA, November 21, 2017 /EINPresswire.com/ — Dental CAD/CAM Market:

Executive Summary

Form past few years, Computer-Aided Design and Computer-Aided Manufacturing (CAD/CAM) have invaded many practices and is so precise that dental restorations made by CAD/CAM often fits more better than those made in a dental lab. Patient satisfaction is being increased simply because the tooth gets repaired in a single day instead of having to return for repeat appointments. CAD/CAM dentistry technology is helping patients move on faster than ever before. By using the technology dentist can completely control the final result.

Dental CAD/CAM market has been segmented on the basis of type of product which comprises of in-lab system, and in-office system. On the basis of products, market is segmented into equipment which is sub-segmented in to milling machines and scanners, and software. On the basis of application, market is segmented into crowns, dentures, bridges, veneers and inlays/onlays. On the basis of end user, market is segmented into dental laboratory, dental clinic, and research/academic institutes.

Globally the market for Dental CAD/CAM is increasing rapidly. Globally the market for dental CAD/CAM is expected to grow at the rate of about 8.1% from 2016 to 2027.

Request Sample Report @ https://www.wiseguyreports.com/sample-request/1267832-dental-cad-cam-market-research-report-global-forecast-to-2027

Key Players

The key players profiled in the research report are Align Technology, Inc., Axsys Incorporated, B&D Dental Technologies, DATRON AG, Dentsply Sirona, KaVo Dental GmbH, Nobel Biocare (Part of Danaher Corporation), PLANMECA OY, Roland DGA Corporation, Straumann, Yenadent Ltd, 3Shape A/S and others.

Study Objectives:

Ø To provide insights about factors, influencing and affecting the market growth.

Ø To provide historically and forecast revenue of the market segments and sub-segments with respect to regional markets and their countries.

Ø To provide historical and forecast revenue of the market segments based on type of product, procedure component, by application, and end users.

Ø To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market.

Target Audience

Dental CAD/CAM service providers
Dental CAD/CAM equipment manufacturers and suppliers
Contract Research Organizations (CROs)
Research and Development (R&D) Companies
Government Research Laboratories
Independent Research Laboratories
Government and Independent Regulatory Authorities
Market Research and Consulting Service Providers
Academic Institutes and Universities

For further information on this report, visit – https://www.wiseguyreports.com/enquiry/1267832-dental-cad-cam-market-research-report-global-forecast-to-2027

Key Findings

The dental CAD/CAM global market and is expected to reach $3.33 billion by 2027.
Equipment holds the largest share of 89% of the market.
Europe holds the largest market share of 42.2% of dental CAD/CAM market and is anticipated to reach US$ 1,458.0 billion by the end of forecast period.

Globally, Asia-Pacific the fastest growing region and expected to grow at the rate of 8.5% during the forecast period.
The reports also cover country level analysis:

America

North America
Europe

Western Europe

Germany
France
Italy
Spain
UK
Rest of Western Europe
Eastern Europe
Asia

China
India
Japan
South Korea
Rest of Asia
Middle East & Africa

Continuous…

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1267832

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire